Literature DB >> 646923

Relationship of cell-mediated cytotoxicity against melanoma cells to prognosis in melanoma patients.

P Hershey, A Edwards, G W Milton, W H McCarthy.   

Abstract

The cell-mediated cytotoxicity (CMC) of blood mononuclear cells against cultured human melanoma cells was measured in patients after surgical removal of localized melanoma, at a time when they were considered on clinical grounds to be free of melanoma. It was found that the distribution of CMC values against melanoma cells in melanoma patients was different from that in control subjects, and several sub-populations of melanoma patients were evident on the basis of these measurements. No difference in distribution of CMC values was found against non-melanoma cells, which suggested the changes were specific for melanoma. The proportion of patients with recurrence of melanoma was compared between the patient groups with low, normal or high CMC values against cultured melanoma cells after surgery. Analysis for periods extending to 2 years showed that patients with low CMC values after surgery had a significantly higher incidence of recurrence from melanoma than patients with normal or high CMC values. These results suggest there may be a sub-group of melanoma patients who have intrinsically low CMC against melanoma cells, and that this may be an important predisposing factor in the development of recurrent melanoma.

Entities:  

Mesh:

Year:  1978        PMID: 646923      PMCID: PMC2009547          DOI: 10.1038/bjc.1978.78

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  27 in total

1.  Specificities in natural cell-mediated cytotoxicity by the cross-competition assay.

Authors:  M Takasugi; D Koide; A Ramseyer
Journal:  Int J Cancer       Date:  1977-03-15       Impact factor: 7.396

2.  Natural cytotoxic reactivity of human lymphocytes against a myeloid cell line: characterization of effector cells.

Authors:  W H West; G B Cannon; H D Kay; G D Bonnard; R B Herberman
Journal:  J Immunol       Date:  1977-01       Impact factor: 5.422

3.  Cellular immunity to human urinary bladder carcinoma. I. Correlation to clinical stage and radiotherapy.

Authors:  C O'Toole; P Perlmann; B Unsgaard; G Moberger; F Edsmyr
Journal:  Int J Cancer       Date:  1972-07-15       Impact factor: 7.396

4.  Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g.

Authors:  A Böyum
Journal:  Scand J Clin Lab Invest Suppl       Date:  1968

5.  Studies on specificity of cell-mediated immunity to human tumors.

Authors:  M Takasugi; M R Mickey; P I Terasaki
Journal:  J Natl Cancer Inst       Date:  1974-12       Impact factor: 13.506

6.  "Natural" killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype.

Authors:  R Kiessling; E Klein; H Wigzell
Journal:  Eur J Immunol       Date:  1975-02       Impact factor: 5.532

7.  Decline of natural nonselective cell-mediated cytotoxicity in patients with tumor progression.

Authors:  M Takasugi; A Ramseyer; J Takasugi
Journal:  Cancer Res       Date:  1977-02       Impact factor: 12.701

8.  Immunological monitoring and immunotherapy in carcinoma of the lung.

Authors:  J L Weese; R B Herberman; E Perlin; M Mills; W Heims; J Blom; D Green; J Reid; S Bellinger; I Law; J L McCoy; J H Dean; G B Cannon; J Djeu
Journal:  Int J Cancer       Date:  1976-12-15       Impact factor: 7.396

9.  Antigens on melanoma cells detected by leukocyte dependent antibody assays of human melanoma antisera.

Authors:  P Hersey; M Honeyman; A Edwards; E Adams; W H McCarthy
Journal:  Int J Cancer       Date:  1976-11-15       Impact factor: 7.396

10.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.

Authors:  R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith
Journal:  Br J Cancer       Date:  1977-01       Impact factor: 7.640

View more
  8 in total

Review 1.  Relevance of the T cell receptor for immunotherapy of cancer.

Authors:  E Weidmann; M Trucco; T L Whiteside
Journal:  Cancer Immunol Immunother       Date:  1994-07       Impact factor: 6.968

2.  Deficient natural killer cell activity in a patient with Fanconi's anaemia and squamous cell carcinoma. Association with defect in interferon release.

Authors:  P Hersey; A Edwards; R Lewis; A Kemp; J McInnes
Journal:  Clin Exp Immunol       Date:  1982-04       Impact factor: 4.330

Review 3.  The biology of the human natural killer cell.

Authors:  J C Roder; H F Pross
Journal:  J Clin Immunol       Date:  1982-10       Impact factor: 8.317

4.  Inability of ovarian cancers to upregulate their MHC-class I surface expression marks their aggressiveness and increased susceptibility to NK cell-mediated cytotoxicity.

Authors:  Nishant Chovatiya; Kawaljit Kaur; Sara Huerta-Yepez; Po-Chun Chen; Adam Neal; Gabriella DiBernardo; Serhat Gumrukcu; Sanaz Memarzadeh; Anahid Jewett
Journal:  Cancer Immunol Immunother       Date:  2022-05-04       Impact factor: 6.630

5.  Human spleen cells mediating natural killing: altered natural cytotoxicity of spleen effector cells from patients with carcinoma.

Authors:  S A Ali; C M Hawrylowicz; J Peel; C Griffith; R C Ress
Journal:  J Cancer Res Clin Oncol       Date:  1983       Impact factor: 4.553

6.  Natural cytotoxicity of lymphocytes and monocytes and its augmentation by OK432 in melanoma patients.

Authors:  E Yanagawa; A Uchida; E M Kokoschka; M Micksche
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

7.  Relationship of natural killer-cell activity to rhesus antigens in man.

Authors:  P Hersey; A Edwards; C Trilivas; H Shaw; G W Milton
Journal:  Br J Cancer       Date:  1979-03       Impact factor: 7.640

8.  Low natural-killer-cell activity in familial melanoma patients and their relatives.

Authors:  P Hersey; A Edwards; M Honeyman; W H McCarthy
Journal:  Br J Cancer       Date:  1979-07       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.